• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 201

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Psychedelics Weekly – Investors Form REIT for Psychedelic Therapy, Diplo Runs a Marathon on LSD, and Is Cannabis a Psychedelic?

PT402 – Magic, Virtual Reality, and Ketamine & Internal Family Systems

Numinus to Host Q2 2023 Results Conference Call on April 13, 2023

Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial

Interview With Yaron Conforti, Novamind

5-MeO-DMT: Can ‘Toad Juice’ Cure Depression?

The World’s First Psychedelic ETF Just Launched: Here’s Why That Matters

How Red Light Holland Is Bringing Psilocybin Truffles Mainstream

Interview With Carlos Tanner

Why Ayahuasca Is Miley Cyrus’ ‘Favorite’ Drug

Patent Combining Psychedelics with Cannabinoids Allowed by USPTO

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including...

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future...

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275...

1...200201202...204Page 201 of 204

EDITOR PICKS

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND...

Psychedelics Weekly – Investors Form REIT for Psychedelic Therapy, Diplo Runs...

PT402 – Magic, Virtual Reality, and Ketamine & Internal Family Systems

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©